Background. The role of N6-methyladenosine long noncoding RNAs (lncRNAs) in colorectal cancer (CRC) is elusive. Materials and Methods. We identified m6A-associated lncRNAs by using the data gathered from The Cancer Genome Atlas (TCGA) and stratified CRC patients into different subgroups. Cox regression analysis was performed to construct an m6A-associated lncRNA signature. The role of this signature in the immune microenvironment and prognosis was dissected subsequently. Finally, a gene set enrichment analysis (GSEA) was conducted to predict the possible mechanisms based on the signature. Results. Three m6A-associated clusters were constructed from 866 differentially expressed lncRNAs. Cluster 2 had poor prognosis and low immune cell infiltration. An m6A-associated lncRNA signature consisting of 14 lncRNAs was constructed and recognized as an independent prognostic indicator of CRC by using survival analysis and receiver operating characteristic (ROC) curves. The clinical features and immune cell infiltration status were significantly different in patients stratified by the risk score. Furthermore, GSEA showed that the P53 pathway and natural killer cell-mediated cytotoxicity were more enriched in the low-risk group. Conclusion. Our data revealed that m6A-associated lncRNAs could be potential prognostic indicators of immunogenicity in CRC.

No abstract

Background The role of N6-methyladenosine long non-coding RNAs (lncRNAs) in colorectal cancer (CRC) is elusive. Materials and Methods We identified m6A-associated lncRNAs by using the data gathered from The Cancer Genome Atlas (TCGA) and stratified CRC patients into different subgroups. Cox-regression analysis were performed to construct a m6A-associated lncRNA signature. The role of this signature in immune microenvironment and prognosis was dissected subsequently. Finally, a gene set enrichment analysis (GSEA) was conducted to predict the possible mechanisms based on the signature. Results Three m6A-associated clusters were constructed from 866 differentially expressed lncRNAs. Cluster 2 had poor prognosis and low immune cell infiltration. A m6A-associated lncRNA signature consisting of 14 lncRNAs was constructed, and recognized as an independent prognostic indicator of CRC by using survival analysis and receiver operating characteristic (ROC) curves. The clinical features and immune cell infiltration status were significantly different in patients stratified by risk score. Furthermore, GSEA showed that P53 pathway and Natural killer cell mediated cytotoxicity were more enriched in the low-risk group. Conclusion Our data revealed that m6A-associated lncRNAs could be potential prognostic indicator of immunogenicity in CRC.

Background: The role of N6-methyladenosine medicated long non-coding RNAs (lncRNAs) is elusive in colorectal cancer (CRC). Materials and Methods: We identified m6A-associated lncRNAs by using the data gathered from The Cancer Genome Atlas (TCGA) and stratified CRC patients into different subgroups. Cox-regression analysis were performed to construct a m6A-associated lncRNA signature. And the role of this signature in prognosis and immune microenvironment was dissected subsequently. Finally, a gene set enrichment analysis (GSEA) were executed to predict the possible bio-mechanisms on the basis of the signature.Results: Three m6A-associated clusters were constructed from 866 differentially expressed lncRNAs. Cluster 2 had poor prognosis and low immune cell infiltration. A m6A-associated lncRNA signature consisting of 14 lncRNAs was constructed, and recognized as an independent prognostic indicator in CRC by using survival analysis and receiver operating characteristic (ROC) curves. The clinical features and immune cell infiltration status were significantly different in the patients stratified by risk score. Furthermore, GSEA showed that P53 pathway and Natural killer cell mediated cytotoxicity were more enriched in the low risk group.Conclusion: Our data revealed that m6A-associated lncRNAs could be potential prognostic and immunogenicity indicators in CRC.